Last reviewed · How we verify

NCT02481817: NoAAC PR-02

Treatment Alternatives in iSGS (NoAAC PR-02 Study)

Completed Last updated 28 October 2021
What this trial tests

trial testing Endoscopic dilation of subglottic stenosis in Idiopathic Subglottic Stenosis (iSGS) in 1,239 participants. Completed in 10 September 2020.

Timeline
28 August 2015
Primary endpoint
10 September 2020
10 September 2020

Quick facts

Lead sponsorVanderbilt University Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,239
Start date28 August 2015
Primary completion10 September 2020
Estimated completion10 September 2020
Sites42 locations across United Kingdom, United States, Australia, Iceland

Drugs / interventions tested

Conditions studied

Sponsor

Vanderbilt University Medical Center

Who can join

18 and older, any sex, with Idiopathic Subglottic Stenosis (iSGS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aimed at answering the questions; (1) How well do the most commonly used treatments in iSGS work? and (2) What quality-of-life trade-offs are associated with each approach? With the results of this trial, the investigators hope to provide information to iSGS patients: (1) Given my personal characteristics, conditions, and preferences, what should I expect will happen to me? and (2) What are my options, and what are the potential benefits and harms of these options?

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial.
    Gelbard A, Shyr Y, Berry L, Hillel AT, et al · · 2018 · cited 42× · PMID 29643170 · DOI 10.1136/bmjopen-2018-022243

Verify or expand the search:

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02481817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing